Pulmonary Idiopathic Arterial Hypertension Clinical Trial
Official title:
The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.
| Verified date | October 2018 |
| Source | Unidad de Investigacion Clinica en Medicina S.C. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury
and the capacity for repair.
Current evidence established that endothelial progenitor cells (EPC) participate in several
models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery
disease, etc. However EPC in the setting of PAH is less well established. The target of this
study is to demonstrate if the number of EPC is increased in a mexican population of patients
with PAH.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | October 2016 |
| Est. primary completion date | July 2008 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization. The ability to walk >50 m during a standardized 6-min walk test. Exclusion Criteria: - Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded. |
| Country | Name | City | State |
|---|---|---|---|
| Mexico | Unidad de Investigacion Clinica en Medicina SC. | Monterrey | Nuevo Leon |
| Lead Sponsor | Collaborator |
|---|---|
| Unidad de Investigacion Clinica en Medicina S.C. |
Mexico,